Schizophrenia - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：389頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Schizophrenia - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Schizophrenia - Pipeline Review, H1 2014’, provides an overview of the Schizophrenia’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Schizophrenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schizophrenia and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Schizophrenia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Schizophrenia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Schizophrenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Schizophrenia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Schizophrenia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Schizophrenia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Schizophrenia - Pipeline Review, H1 2014’, provides an overview of the Schizophrenia’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Schizophrenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schizophrenia and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Schizophrenia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Schizophrenia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Schizophrenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Schizophrenia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Schizophrenia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Schizophrenia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
Introduction 7
Schizophrenia Overview 8
Therapeutics Development 9
Schizophrenia - Therapeutics under Development by Companies 11
Schizophrenia - Therapeutics under Investigation by Universities/Institutes 18
Schizophrenia - Pipeline Products Glance 20
Schizophrenia - Products under Development by Companies 24
Schizophrenia - Products under Investigation by Universities/Institutes 33
Schizophrenia - Companies Involved in Therapeutics Development 34
Schizophrenia - Therapeutics Assessment 113
Drug Profiles 134
Schizophrenia - Recent Pipeline Updates 319
Schizophrenia - Dormant Projects 359
Schizophrenia - Discontinued Products 362
Schizophrenia - Product Development Milestones 363
Appendix 372
List of Tables
Number of Products under Development for Schizophrenia, H1 2014 25
Number of Products under Development for Schizophrenia - Comparative Analysis, H1 2014 26
Number of Products under Development by Companies, H1 2014 28
Number of Products under Development by Companies, H1 2014 (Contd..1) 29
Number of Products under Development by Companies, H1 2014 (Contd..2) 30
Number of Products under Development by Companies, H1 2014 (Contd..3) 31
Number of Products under Development by Companies, H1 2014 (Contd..4) 32
Number of Products under Development by Companies, H1 2014 (Contd..5) 33
Number of Products under Investigation by Universities/Institutes, H1 2014 35
Comparative Analysis by Late Stage Development, H1 2014 36
Comparative Analysis by Clinical Stage Development, H1 2014 37
Comparative Analysis by Early Stage Development, H1 2014 38
Comparative Analysis by Unknown Stage Development, H1 2014 39
Products under Development by Companies, H1 2014 40
Products under Development by Companies, H1 2014 (Contd..1) 41
Products under Development by Companies, H1 2014 (Contd..2) 42
Products under Development by Companies, H1 2014 (Contd..3) 43
Products under Development by Companies, H1 2014 (Contd..4) 44
Products under Development by Companies, H1 2014 (Contd..5) 45
Products under Development by Companies, H1 2014 (Contd..6) 46
Products under Development by Companies, H1 2014 (Contd..7) 47
Products under Development by Companies, H1 2014 (Contd..8) 48
Products under Investigation by Universities/Institutes, H1 2014 49
Schizophrenia - Pipeline by Bristol-Myers Squibb Company, H1 2014 50
Schizophrenia - Pipeline by Johnson & Johnson, H1 2014 51
Schizophrenia - Pipeline by Boehringer Ingelheim GmbH, H1 2014 52
Schizophrenia - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 53
Schizophrenia - Pipeline by Eli Lilly and Company, H1 2014 54
Schizophrenia - Pipeline by Athersys, Inc., H1 2014 55
Schizophrenia - Pipeline by Alkermes Plc, H1 2014 56
Schizophrenia - Pipeline by Merck & Co., Inc., H1 2014 57
Schizophrenia - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014 58
Schizophrenia - Pipeline by Taisho Pharmaceutical Co., Ltd., H1 2014 59
Schizophrenia - Pipeline by NeuroDerm Ltd., H1 2014 60
Schizophrenia - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 61
Schizophrenia - Pipeline by Zogenix, Inc., H1 2014 62
Schizophrenia - Pipeline by Neurocrine Biosciences, Inc., H1 2014 63
Schizophrenia - Pipeline by Novartis AG, H1 2014 64
Schizophrenia - Pipeline by EnVivo Pharmaceuticals, H1 2014 65
Schizophrenia - Pipeline by Astellas Pharma Inc., H1 2014 66
Schizophrenia - Pipeline by Egis Gyogyszergyar Nyrt, H1 2014 67
Schizophrenia - Pipeline by Richter Gedeon Nyrt., H1 2014 68
Schizophrenia - Pipeline by H. Lundbeck A/S, H1 2014 69
Schizophrenia - Pipeline by Les Laboratoires Servier SAS, H1 2014 70
Schizophrenia - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2014 71
Schizophrenia - Pipeline by Pfizer Inc., H1 2014 72
Schizophrenia - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 73
Schizophrenia - Pipeline by Zydus Cadila Healthcare Limited, H1 2014 74
Schizophrenia - Pipeline by XTL Biopharmaceuticals Ltd., H1 2014 75
Schizophrenia - Pipeline by NuPathe Inc., H1 2014 76
Schizophrenia - Pipeline by Addex Therapeutics, H1 2014 77
Schizophrenia - Pipeline by Evotec AG, H1 2014 78
Schizophrenia - Pipeline by GW Pharmaceuticals plc, H1 2014 79
Schizophrenia - Pipeline by Bionomics Limited, H1 2014 80
Schizophrenia - Pipeline by Acadia Pharmaceuticals Inc., H1 2014 81
Schizophrenia - Pipeline by Dongwha Pharm Co., Ltd., H1 2014 82
Schizophrenia - Pipeline by Biotie Therapies Corp., H1 2014 83
Schizophrenia - Pipeline by Suven Life Sciences Ltd., H1 2014 84
Schizophrenia - Pipeline by Newron Pharmaceuticals S.p.A., H1 2014 85
Schizophrenia - Pipeline by Jiangsu Nhwa Pharma Corporation, H1 2014 86
Schizophrenia - Pipeline by Snowdon Inc., H1 2014 87
Schizophrenia - Pipeline by Domain Therapeutics SA, H1 2014 88
Schizophrenia - Pipeline by Critical Pharmaceuticals Limited, H1 2014 89
Schizophrenia - Pipeline by Curemark, LLC, H1 2014 90
Schizophrenia - Pipeline by AGY Therapeutics, Inc., H1 2014 91
Schizophrenia - Pipeline by Fabre-Kramer Pharmaceuticals, Inc., H1 2014 92
Schizophrenia - Pipeline by GP Pharm, S.A., H1 2014 93
Schizophrenia - Pipeline by Omeros Corporation, H1 2014 94
Schizophrenia - Pipeline by Laboratorios Farmaceuticos Rovi, S.A., H1 2014 95
Schizophrenia - Pipeline by Intra-Cellular Therapies, Inc., H1 2014 96
Schizophrenia - Pipeline by Peptron, Inc., H1 2014 97
Schizophrenia - Pipeline by Targacept, Inc., H1 2014 98
Schizophrenia - Pipeline by Vanda Pharmaceuticals Inc., H1 2014 99
Schizophrenia - Pipeline by Galenea Corp., H1 2014 100
Schizophrenia - Pipeline by Adamed Sp. z o.o., H1 2014 101
Schizophrenia - Pipeline by KemPharm, Inc., H1 2014 102
Schizophrenia - Pipeline by Heptares Therapeutics Ltd., H1 2014 103
Schizophrenia - Pipeline by Ascendis Pharma A/S, H1 2014 104
Schizophrenia - Pipeline by Otsuka Holdings Co., Ltd., H1 2014 105
Schizophrenia - Pipeline by BIOPROJET SCR, H1 2014 106
Schizophrenia - Pipeline by Reviva Pharmaceuticals Inc., H1 2014 107
Schizophrenia - Pipeline by Promentis Pharmaceuticals, Inc., H1 2014 108
Schizophrenia - Pipeline by Naurex, Inc., H1 2014 109
Schizophrenia - Pipeline by Acino Pharma AG, H1 2014 110
Schizophrenia - Pipeline by PharmaNeuroBoost NV, H1 2014 111
Schizophrenia - Pipeline by GeNeuro SA, H1 2014 112
Schizophrenia - Pipeline by Delpor, Inc., H1 2014 113
Schizophrenia - Pipeline by Mnemosyne Pharmaceuticals, Inc., H1 2014 114
Schizophrenia - Pipeline by Aestus Therapeutics, Inc., H1 2014 115
Schizophrenia - Pipeline by Rottapharm|Madaus, H1 2014 116
Schizophrenia - Pipeline by Sunovion Pharmaceuticals Inc., H1 2014 117
Schizophrenia - Pipeline by BioCrea GmbH, H1 2014 118
Schizophrenia - Pipeline by Lead Discovery Center GmbH, H1 2014 119
Schizophrenia - Pipeline by BRAINco Biopharma, S.L., H1 2014 120
Schizophrenia - Pipeline by Echo Pharmaceuticals B.V., H1 2014 121
Schizophrenia - Pipeline by Cerecor Inc., H1 2014 122
Schizophrenia - Pipeline by Karuna Pharmaceuticals Inc., H1 2014 123
Schizophrenia - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2014 124
Schizophrenia - Pipeline by Sage Therapeutics, H1 2014 125
Schizophrenia - Pipeline by AbbVie Inc., H1 2014 126
Schizophrenia - Pipeline by Angita B.V., H1 2014 127
Schizophrenia - Pipeline by Inventiva SAS, H1 2014 128
Assessment by Monotherapy Products, H1 2014 129
Assessment by Combination Products, H1 2014 130
Number of Products by Stage and Target, H1 2014 133
Number of Products by Stage and Mechanism of Action, H1 2014 139
Number of Products by Stage and Route of Administration, H1 2014 146
Number of Products by Stage and Molecule Type, H1 2014 149
Schizophrenia Therapeutics - Recent Pipeline Updates, H1 2014 335
Schizophrenia - Dormant Projects, H1 2014 375
Schizophrenia - Discontinued Products, H1 2014 378
List of Figures
Number of Products under Development for Schizophrenia, H1 2014 25
Number of Products under Development for Schizophrenia - Comparative Analysis, H1 2014 26
Number of Products under Development by Companies, H1 2014 27
Number of Products under Investigation by Universities/Institutes, H1 2014 34
Comparative Analysis by Late Stage Development, H1 2014 36
Comparative Analysis by Clinical Stage Development, H1 2014 37
Comparative Analysis by Early Stage Products, H1 2014 38
Comparative Analysis by Unknown Stage Development, H1 2014 39
Assessment by Monotherapy Products, H1 2014 129
Number of Products by Top 10 Target, H1 2014 131
Number of Products by Stage and Top 10 Target, H1 2014 132
Number of Products by Top 10 Mechanism of Action, H1 2014 137
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 138
Number of Products by Top 10 Route of Administration, H1 2014 144
Number of Products by Stage and Top 10 Route of Administration, H1 2014 145
Number of Products by Top 10 Molecule Type, H1 2014 147
Number of Products by Stage and Top 10 Molecule Type, H1 2014 148
Table of Contents 2
Introduction 7
Schizophrenia Overview 8
Therapeutics Development 9
Schizophrenia - Therapeutics under Development by Companies 11
Schizophrenia - Therapeutics under Investigation by Universities/Institutes 18
Schizophrenia - Pipeline Products Glance 20
Schizophrenia - Products under Development by Companies 24
Schizophrenia - Products under Investigation by Universities/Institutes 33
Schizophrenia - Companies Involved in Therapeutics Development 34
Schizophrenia - Therapeutics Assessment 113
Drug Profiles 134
Schizophrenia - Recent Pipeline Updates 319
Schizophrenia - Dormant Projects 359
Schizophrenia - Discontinued Products 362
Schizophrenia - Product Development Milestones 363
Appendix 372
List of Tables
Number of Products under Development for Schizophrenia, H1 2014 25
Number of Products under Development for Schizophrenia - Comparative Analysis, H1 2014 26
Number of Products under Development by Companies, H1 2014 28
Number of Products under Development by Companies, H1 2014 (Contd..1) 29
Number of Products under Development by Companies, H1 2014 (Contd..2) 30
Number of Products under Development by Companies, H1 2014 (Contd..3) 31
Number of Products under Development by Companies, H1 2014 (Contd..4) 32
Number of Products under Development by Companies, H1 2014 (Contd..5) 33
Number of Products under Investigation by Universities/Institutes, H1 2014 35
Comparative Analysis by Late Stage Development, H1 2014 36
Comparative Analysis by Clinical Stage Development, H1 2014 37
Comparative Analysis by Early Stage Development, H1 2014 38
Comparative Analysis by Unknown Stage Development, H1 2014 39
Products under Development by Companies, H1 2014 40
Products under Development by Companies, H1 2014 (Contd..1) 41
Products under Development by Companies, H1 2014 (Contd..2) 42
Products under Development by Companies, H1 2014 (Contd..3) 43
Products under Development by Companies, H1 2014 (Contd..4) 44
Products under Development by Companies, H1 2014 (Contd..5) 45
Products under Development by Companies, H1 2014 (Contd..6) 46
Products under Development by Companies, H1 2014 (Contd..7) 47
Products under Development by Companies, H1 2014 (Contd..8) 48
Products under Investigation by Universities/Institutes, H1 2014 49
Schizophrenia - Pipeline by Bristol-Myers Squibb Company, H1 2014 50
Schizophrenia - Pipeline by Johnson & Johnson, H1 2014 51
Schizophrenia - Pipeline by Boehringer Ingelheim GmbH, H1 2014 52
Schizophrenia - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 53
Schizophrenia - Pipeline by Eli Lilly and Company, H1 2014 54
Schizophrenia - Pipeline by Athersys, Inc., H1 2014 55
Schizophrenia - Pipeline by Alkermes Plc, H1 2014 56
Schizophrenia - Pipeline by Merck & Co., Inc., H1 2014 57
Schizophrenia - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014 58
Schizophrenia - Pipeline by Taisho Pharmaceutical Co., Ltd., H1 2014 59
Schizophrenia - Pipeline by NeuroDerm Ltd., H1 2014 60
Schizophrenia - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 61
Schizophrenia - Pipeline by Zogenix, Inc., H1 2014 62
Schizophrenia - Pipeline by Neurocrine Biosciences, Inc., H1 2014 63
Schizophrenia - Pipeline by Novartis AG, H1 2014 64
Schizophrenia - Pipeline by EnVivo Pharmaceuticals, H1 2014 65
Schizophrenia - Pipeline by Astellas Pharma Inc., H1 2014 66
Schizophrenia - Pipeline by Egis Gyogyszergyar Nyrt, H1 2014 67
Schizophrenia - Pipeline by Richter Gedeon Nyrt., H1 2014 68
Schizophrenia - Pipeline by H. Lundbeck A/S, H1 2014 69
Schizophrenia - Pipeline by Les Laboratoires Servier SAS, H1 2014 70
Schizophrenia - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2014 71
Schizophrenia - Pipeline by Pfizer Inc., H1 2014 72
Schizophrenia - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 73
Schizophrenia - Pipeline by Zydus Cadila Healthcare Limited, H1 2014 74
Schizophrenia - Pipeline by XTL Biopharmaceuticals Ltd., H1 2014 75
Schizophrenia - Pipeline by NuPathe Inc., H1 2014 76
Schizophrenia - Pipeline by Addex Therapeutics, H1 2014 77
Schizophrenia - Pipeline by Evotec AG, H1 2014 78
Schizophrenia - Pipeline by GW Pharmaceuticals plc, H1 2014 79
Schizophrenia - Pipeline by Bionomics Limited, H1 2014 80
Schizophrenia - Pipeline by Acadia Pharmaceuticals Inc., H1 2014 81
Schizophrenia - Pipeline by Dongwha Pharm Co., Ltd., H1 2014 82
Schizophrenia - Pipeline by Biotie Therapies Corp., H1 2014 83
Schizophrenia - Pipeline by Suven Life Sciences Ltd., H1 2014 84
Schizophrenia - Pipeline by Newron Pharmaceuticals S.p.A., H1 2014 85
Schizophrenia - Pipeline by Jiangsu Nhwa Pharma Corporation, H1 2014 86
Schizophrenia - Pipeline by Snowdon Inc., H1 2014 87
Schizophrenia - Pipeline by Domain Therapeutics SA, H1 2014 88
Schizophrenia - Pipeline by Critical Pharmaceuticals Limited, H1 2014 89
Schizophrenia - Pipeline by Curemark, LLC, H1 2014 90
Schizophrenia - Pipeline by AGY Therapeutics, Inc., H1 2014 91
Schizophrenia - Pipeline by Fabre-Kramer Pharmaceuticals, Inc., H1 2014 92
Schizophrenia - Pipeline by GP Pharm, S.A., H1 2014 93
Schizophrenia - Pipeline by Omeros Corporation, H1 2014 94
Schizophrenia - Pipeline by Laboratorios Farmaceuticos Rovi, S.A., H1 2014 95
Schizophrenia - Pipeline by Intra-Cellular Therapies, Inc., H1 2014 96
Schizophrenia - Pipeline by Peptron, Inc., H1 2014 97
Schizophrenia - Pipeline by Targacept, Inc., H1 2014 98
Schizophrenia - Pipeline by Vanda Pharmaceuticals Inc., H1 2014 99
Schizophrenia - Pipeline by Galenea Corp., H1 2014 100
Schizophrenia - Pipeline by Adamed Sp. z o.o., H1 2014 101
Schizophrenia - Pipeline by KemPharm, Inc., H1 2014 102
Schizophrenia - Pipeline by Heptares Therapeutics Ltd., H1 2014 103
Schizophrenia - Pipeline by Ascendis Pharma A/S, H1 2014 104
Schizophrenia - Pipeline by Otsuka Holdings Co., Ltd., H1 2014 105
Schizophrenia - Pipeline by BIOPROJET SCR, H1 2014 106
Schizophrenia - Pipeline by Reviva Pharmaceuticals Inc., H1 2014 107
Schizophrenia - Pipeline by Promentis Pharmaceuticals, Inc., H1 2014 108
Schizophrenia - Pipeline by Naurex, Inc., H1 2014 109
Schizophrenia - Pipeline by Acino Pharma AG, H1 2014 110
Schizophrenia - Pipeline by PharmaNeuroBoost NV, H1 2014 111
Schizophrenia - Pipeline by GeNeuro SA, H1 2014 112
Schizophrenia - Pipeline by Delpor, Inc., H1 2014 113
Schizophrenia - Pipeline by Mnemosyne Pharmaceuticals, Inc., H1 2014 114
Schizophrenia - Pipeline by Aestus Therapeutics, Inc., H1 2014 115
Schizophrenia - Pipeline by Rottapharm|Madaus, H1 2014 116
Schizophrenia - Pipeline by Sunovion Pharmaceuticals Inc., H1 2014 117
Schizophrenia - Pipeline by BioCrea GmbH, H1 2014 118
Schizophrenia - Pipeline by Lead Discovery Center GmbH, H1 2014 119
Schizophrenia - Pipeline by BRAINco Biopharma, S.L., H1 2014 120
Schizophrenia - Pipeline by Echo Pharmaceuticals B.V., H1 2014 121
Schizophrenia - Pipeline by Cerecor Inc., H1 2014 122
Schizophrenia - Pipeline by Karuna Pharmaceuticals Inc., H1 2014 123
Schizophrenia - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2014 124
Schizophrenia - Pipeline by Sage Therapeutics, H1 2014 125
Schizophrenia - Pipeline by AbbVie Inc., H1 2014 126
Schizophrenia - Pipeline by Angita B.V., H1 2014 127
Schizophrenia - Pipeline by Inventiva SAS, H1 2014 128
Assessment by Monotherapy Products, H1 2014 129
Assessment by Combination Products, H1 2014 130
Number of Products by Stage and Target, H1 2014 133
Number of Products by Stage and Mechanism of Action, H1 2014 139
Number of Products by Stage and Route of Administration, H1 2014 146
Number of Products by Stage and Molecule Type, H1 2014 149
Schizophrenia Therapeutics - Recent Pipeline Updates, H1 2014 335
Schizophrenia - Dormant Projects, H1 2014 375
Schizophrenia - Discontinued Products, H1 2014 378
List of Figures
Number of Products under Development for Schizophrenia, H1 2014 25
Number of Products under Development for Schizophrenia - Comparative Analysis, H1 2014 26
Number of Products under Development by Companies, H1 2014 27
Number of Products under Investigation by Universities/Institutes, H1 2014 34
Comparative Analysis by Late Stage Development, H1 2014 36
Comparative Analysis by Clinical Stage Development, H1 2014 37
Comparative Analysis by Early Stage Products, H1 2014 38
Comparative Analysis by Unknown Stage Development, H1 2014 39
Assessment by Monotherapy Products, H1 2014 129
Number of Products by Top 10 Target, H1 2014 131
Number of Products by Stage and Top 10 Target, H1 2014 132
Number of Products by Top 10 Mechanism of Action, H1 2014 137
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 138
Number of Products by Top 10 Route of Administration, H1 2014 144
Number of Products by Stage and Top 10 Route of Administration, H1 2014 145
Number of Products by Top 10 Molecule Type, H1 2014 147
Number of Products by Stage and Top 10 Molecule Type, H1 2014 148
